On February 5, 2018 Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) reported that it’s President, Chief Executive Officer and co-founder, Steven J. Mento, Ph.D., and Conatus Executive Vice President, Chief Operating Officer and Chief Financial Officer, Keith W. Marshall, Ph.D., M.B.A., will focus on the company’s expected announcements of clinical trial results and strategic development activities, in a presentation and in scheduled meetings with members of the investment community in New York next week (Press release, Conatus Pharmaceuticals, FEB 5, 2018, View Source [SID1234523755]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This is an exciting time for Conatus. We are now rapidly approaching four scheduled Phase 2b clinical trial readouts from our lead development program in 2018 and 2019, along with multiple parallel pathways to expanding our development pipeline," said Dr. Mento, "and we believe Conatus is advancing well toward the next chapter in the company’s evolution."
"With the funds provided by our collaboration with Novartis, including anticipated reimbursements for 50% of the costs for the four ongoing clinical trials," said Dr. Marshall, "the remaining emricasan development is fully funded. In addition, we believe these financial resources, without including any potential milestone payments under the Novartis collaboration, are sufficient to maintain operations through completion of all four Phase 2b clinical trials by the end of 2019, as well as to fund initial pipeline expansion activities. We will provide additional financial guidance for 2018 with our year-end financial results in early March."
At the Biotechnology Industry Organization (BIO) CEO & Investor Conference BIO CEO & Investor Conference in New York on Monday, February 12, Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 10:30 a.m. ET. An audio webcast and copy of the BIO CEO & Investor Conference presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.
At the SunTrust Robinson Humphrey Orphan Drug Day in New York on Tuesday, February 13, Dr. Mento and Dr. Marshall will conduct a series of meetings with invited institutional investors.